Nuclear Medicine Unit, Humanitas Clinical and Research Hospital-IRCCS, Rozzano, Milan, Italy.
Nuclear Medicine Unit, Humanitas Clinical and Research Hospital-IRCCS, Rozzano, Milan, Italy -
Q J Nucl Med Mol Imaging. 2020 Jun;64(2):175-185. doi: 10.23736/S1824-4785.20.03251-3. Epub 2020 Feb 27.
Immune checkpoint inhibitors (ICI) represent a cornerstone in cancer treatment. However, the peculiarity of immune response, determining distinctive response patterns and toxicity events, challenges the conventional response criteria. Therefore, the effective tumor response and the real clinical benefit cannot be demonstrated adequately. In this context, recent studies using 2-deoxy-2-[18F]fluoro-D-glucose ([18F]) positron emission tomography/computed tomography (PET/CT) have shown promising results for therapeutic monitoring during ICI, although further research is needed to confirm its potentials. In this review, we focus on the latest evidences and challenges regarding the assessment of morphological and metabolic parameters in the evaluation of ICI therapy. We will also discuss a wide range of emerging imaging-based biomarkers for anti-checkpoint therapy as well as their challenges in the clinical practice.
免疫检查点抑制剂（ICI）是癌症治疗的基石。然而，免疫反应的特殊性决定了独特的反应模式和毒性事件，这对传统的反应标准提出了挑战。因此，无法充分证明有效的肿瘤反应和真正的临床获益。在这种情况下，最近使用 2-脱氧-2-[18F]氟-D-葡萄糖 ([18F]) 正电子发射断层扫描/计算机断层扫描（PET/CT）的研究表明，在 ICI 治疗期间进行治疗监测具有很大的潜力，但仍需要进一步的研究来证实其潜力。在这篇综述中，我们重点介绍了评估 ICI 治疗中形态学和代谢参数的最新证据和挑战。我们还将讨论一系列新兴的基于成像的抗检查点治疗生物标志物及其在临床实践中的挑战。
